Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis

作者：Chan Wang, Zhuye Qin, Mingming Zhang, Yaping Dai, Luyao Zhang, Wenyan Tian, Yuhua Gong, Sufang Chen, Can Yang, Ping Xu, Xingjuan Shi, Weifeng Zhao, Suraj Timilsina, M. Eric Gershwin, Weichang Chen, Fang Qiu, Xiangdong Liu · 发表于：Journal of Translational Autoimmunity · 年份：2024 · DOI：10.1016/j.jtauto.2024.100239 · 被引用次数：6 · 研究领域：Liver Diseases and Immunity、Drug Transport and Resistance Mechanisms、Systemic Lupus Erythematosus Research

Objectives: Antibodies to gp210 and sp100 are specific and unique anti-nuclear autoantibodies (ANAs) associated with primary biliary cholangitis (PBC). Importantly the presence of anti-gp210 and anti-sp100 responses is indicative of poor clinical outcomes. However, the utility of measuring titers of these antibodies remains unclear. Materials and methods: Using the in-house purified gp210 (HSA108-C18) and sp100 (amino acid position 296-386), we quantitatively measured serum autoantibodies to gp210 and sp100 using chemiluminescence immunoassay (CLIA) in a very large cohort of 390 patients with PBC, including 259 cases with no prior ursodesoxycholic acid (UDCA) treatment and 131 cases with UDCA treatment. We also analyzed serial changes in anti-gp210 and anti-sp100 levels in 245 sequential samples from 88 patients. Results: = 0.042) levels at baseline were independently associated with anti-gp210 concentrations. In serial testing, we observed significant fluctuations in anti-gp210 antibody levels. These fluctuations reflected responsiveness to UDCA therapy, particularly in anti-gp210-positive patients with initially lower concentrations in the stages of disease. Conclusions: Our study reflects that quantitative changes of anti-gp210 antibody are indicative of UDCA responses. There is a great need for newer metrics in PBC and we suggest that a more detailed and longer study of these unique ANAs is warranted.